There is significant interest in the development of 'T cell adjuvants', biocompounds capable of enhancing T cell immune responses against tumors or chronic infections. In order to target diseased tissue for elimination, T cells must recognize antigens via the T cell antigen receptor (TCR), and induce a conformational change in the TCR-associated CD3 complex (v). However, the mechanism(s) by which this occurs, and the precise contribution this makes to T cell immunity, are not completely understood. In this project, we propose to elucidate the protein sequences controlling CD3?c in experiments designed to inform new conceptual models regarding the structural aspects of T cell activation. We will focus on the TCR/CD3 subunits, domains, and amino acid sequences involved in CD3?c. Relevant sequences that are discovered in this manner will be mutated and expressed to ascertain their functional contribution to T cell development and activation. We will also determine the contribution that exogenous provision of CD3?c imparts to T cell function, via the use of a new reagent we have generated. This reagent can induce CD3?c without inducing other T cell signaling, and therefore it is inert to non-antigen-engaged T cells. However, the reagent appears to enhance T cell activation by weak antigens, and thus may represent a novel class of 'T cell adjuvant'. We will examine the ability of this reagent to lower the T cell activation signaling threshold, and to enhance T cell-mediated tumor rejection in mice. The information obtained from these studies will advance our comprehension of antigen recognition by T cells, and point toward CD3?c as molecular target with therapeutic potential.

Public Health Relevance

Recognition of antigen causes the CD3 complex to undergo a conformational change that can enhance T cell immune activity. We will characterize the precise protein sequences that control this CD3 rearrangement, and establish the level of impact it imparts to T cell immune function. Furthermore, a new means of exogenously inducing this CD3 conformational change will be evaluated for its ability to enhance T cell immunity against tumors.

National Institute of Health (NIH)
Research Project (R01)
Project #
Application #
Study Section
Cellular and Molecular Immunology - B Study Section (CMIB)
Program Officer
Quill, Helen R
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Mayo Clinic, Rochester
United States
Zip Code